|Articles|July 1, 2012
- Pharmaceutical Executive-07-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - July 2012
2012 Emerging Pharma Leaders
Advertisement
Articles in this issue
almost 14 years ago
Emerging Pharma Leaders 2012almost 14 years ago
Who Will Pay for New Drugs?almost 14 years ago
Less, But Betteralmost 14 years ago
John Lechleiter on PhRMA and Innovationalmost 14 years ago
Today's Mission Critical: Making Sense of Spending on Clinical Trialsalmost 14 years ago
The Learning Curvealmost 14 years ago
Marketing: Why the Conversation Has Changed — ForeverAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
4
The Evolving Relationship Between FDA and Biotech
5